Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.29824 EPS, expectations were $0.09. Amneal Pharmaceuticals, Inc.
Source: insidermonkey.com
Chintu Patel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Chintu Patel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Chintu Patel Today - Breaking & Trending Today
Amneal Reports First Quarter 2024 Financial Results
‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has...
Source: marketscreener.com
FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
Naloxone hydrochloride (Amneal Pharmaceuticals Inc) is the generic equivalent to OTC narcan (Emergent).
Source: pharmacytimes.com
Amneal to ring Nasdaq closing bell on April 2, 2024
Amneal is celebrating its recent listing on the Nasdaq Stock Exchange.
Source: drugstorenews.com
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange ...
Source: marketscreener.com